ClinicalTrials.gg
CompletedNCT06431763Updated Jul 29, 2026

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

A Phase 4 interventional study of Inclisiran sodium and BPA in Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 55 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.

Enrollment
11th of 24
402 · median 375
Started
2024
with 3 others
Phase 4
7 of 24
3 open now
Registered
18th of 24
by date
Lead sponsor
16 of 24
Novartis Pharmaceuticals

Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 11th largest by enrollment, is one of 4 that started in 2024, is one of 7 in phase 4, and was the 18th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing inclisiran in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study is a phase IV, open-label, randomized study designed to evaluate the efficacy of Inclisiran vs. bempedoic acid (BPA) in 400 adult subjects (≥ 18 years) at very high and high risk for cardiovascular events as defined by the cardiovascular risk categories in the 2019 ESC/EAS guidelines for the management of dyslipidemias (Mach et al 2020) and elevated levels of LDL-C (≥ 70 mg/dL) despite being on a maximally tolerated high-intensity (HI) statin dose (+/- Ezetimibe). Currently, BPA is recommended ahead of injectables by German HTA body (GBA). A head-to-head trial is proposed to provide robust scientific data on the superiority of Inclisiran vs. BPA and to support the early use of Inclisiran.

Read the detailed description

During the screening period study eligibility will be assessed and the participants' individual LDL-C target according to guideline (Mach et al., 2020) will be determined. Among other criteria, at screening, a participant must be on a stable maximally tolerated dose of a HI statin with either atorvastatin ≥40 mg once a day (QD) or rosuvastatin ≥20 mg QD (+/- Ezetimibe [10mg]) for ≥ 4 weeks with which, however, a target LDL-C of \< 70 mg/dL is not reached.

During the open-label treatment period, all participants, who fulfill the inclusion/exclusion criteria, will be randomized at V1 (Day 1) in a 1:1 open-label fashion to either Inclisiran sodium 300 mg s.c. (administered at Day 1 and Day 90) or to BPA tablets 180 mg p.o. (given once daily). Participants will be required to maintain their background lipid-lowering treatment (maximally tolerated statin dose +/- Ezetimibe) unchanged for the duration of the study. The end of treatment (EOT) is reached at day 150.

A Safety-Follow-up call will be conducted 30 days after EOT visit (Day 180).

The overall study duration is approximately 190 days but can vary depending on individual screening and the visit windows allowed for the treatment period and EOS visit.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • LDL-cholesterol
  • atherosclerotic cardiovascular disease
  • Inclisiran
  • bempedoic acid
  • BPA
  • PCSK9 inhibitor
  • head-to-head comparison
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fasting LDL-C ≥ 70 mg/dL at screening
  2. Participants must be on a stable (≥ 4 weeks) and well-tolerated lipid-lowering regimen (with or without Ezetimibe [10mg]) that must include a high-intensity statin therapy with either atorvastatin ≥40 mg QD or rosuvastatin ≥20 mg QD in a maximally tolerated or maximally approved dose at screening
  3. Participants categorized as very high or high CV risk, as defined below:

    • Very high risk participants with at least one of the following:

      • Documented ASCVD: ACS: Unstable angina or myocardial infarction, Stable angina, Coronary revascularization, Unequivocally documented ASCVD upon prior imaging, Stroke and (TIA), Peripheral artery disease (PAD)
      • Diabetes mellitus (DM) with target organ damage (defined as microalbuminuria, retinopathy, or neuropathy), or at least ≥ 3 major risk factors, or early onset of Type 1 DM of long duration (\< 20 years)
      • A calculated SCORE2 ≥ 7.5 % for age \< 50 years; SCORE2 ≥ 10 % for age 50-69 years; SCORE2-OP ≥ 15 % for age ≥ 70 years to estimate 10-year risk of fatal and non-fatal CVD
      • Pre-existing diagnosis of heterozygous familial hyper-cholesterolemia (HeFH) with ASCVD or with another major risk factor OR
    • High risk participants with at least one of the following:

      • Markedly elevated single risk factors, in particular total cholesterol > 310 mg/dL, LDL-C > 190 mg/dL, or blood pressure ≥ 180/110 mmHg
      • Pre-existing diagnosis of HeFH without other major risk factors
      • DM without target organ damage (defined as microalbuminuria, retinopathy, or neuropathy), with DM duration ≥ 10 years or other additional risk factor
      • Moderate chronic kidney disease ( 30-59 mL/min/1.73m2)
      • A calculated SCORE2 2.5 to \< 7.5 % for age \< 50 years; SCORE2 5 to \< 10 % for age 50-69 years; SCORE2-OP 7.5 to \< 15 % for age ≥ 70 years to estimate 10-year risk of fatal and non-fatal CVD as defined by the cardiovascular risk categories in the 2019 ESC/EAS guideline (Mach et al 2020), and updated SCORE2 and SCORE2-OP (Hageman et al 2021, de Vries et al 2021, Visseren et al 2021). Further details for documented ASCVD will be provided in the protocol.
  4. Fasting triglyceride \< 400 mg/dL at screening

Exclusion criteria

Exclusion Criteria:

  1. Acute coronary syndrome, ischemic stroke, peripheral arterial revascularization procedure or amputation due to atherosclerotic disease \< 4 months prior to screening visit or V1.
  2. Planned or expected cardiac, cerebrovascular or peripheral artery surgery or coronary re-vascularization within 6 months after screening visit.
  3. Heart failure class IV at screening or V1.
  4. Participants on more than one other lipid-lowering drug on top of statin at screening visit.
  5. Previous treatment with a mAb directed towards PCSK9 (e.g., evolocumab, alirocumab) or planned use after screening visit.
  6. Previous treatment prior to screening with BPA within 90 days
  7. Previous exposure to Inclisiran or any other non-mAb PCSK9-targeted therapy, either as an or marketed drug.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
402 participants (actual)

Study arms

  • Experimental
    Inclisiran

    Inclisiran treatment on top of background treatment (high intensity statin with/without ezetimibe)

    Drug: Inclisiran sodium

  • Active comparator
    Bempedoic acid (BPA)

    BPA treatment on top of background treatment (high intensity statin with/without ezetimibe)

    Drug: BPA

Interventions

  • 300 mg s.c. administered at day 1 and day 90

    Also known as: PCSK9 inhibitor, siRNA

  • DrugBPA

    180 mg daily per oral

    Also known as: small molecule, ACL inhibitor

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in LDL-C levels

    To demonstrate superiority of Inclisiran compared to BPA, in combination with standard of care (maximally tolerated HI statin dose +/- Ezetimibe) in reducing relative LDL-C levels at Day 150.

    Time frame: Baseline, Day 150

Secondary outcomes

  1. Percent change from baseline in LDL-C levels in patients without Ezetimibe

    To demonstrate superiority of Inclisiran compared to BPA, in patients on maximally tolerated HI statin dose without Ezetimibe in relative reduction of LDL-C levels at Day 150.

    Time frame: Baseline, Day 150

  2. Percent change from baseline in LDL-C levels in patients with Ezetimibe

    To demonstrate superiority of Inclisiran compared to BPA, in patients on maximally tolerated HI statin dose with Ezetimibe in reducing relative LDL-C levels at Day 150.

    Time frame: Baseline, Day 150

  3. Number of participants by individual responsiveness

    Number of patients who qualify for 'sufficient response' based on their individual risk class, defined through on treatment LDL-C levels. For patients classified as 'very high risk', responsiveness is 'achieved' once the LDL-C drops below 55mg/dL, and for patients classified as 'high risk' responsiveness is 'achieved' once the LDL-C \< 70 mg/dL at Day 150.

    Time frame: Day 150

  4. Absolute change from Baseline in LDL-C

    Assess efficacy of Inclisiran compared to BPA in reducing LDL-C (absolute reduction).

    Time frame: Day 150

  5. Percent change from Baseline in LDL-C levels

    Assess efficacy of Inclisiran compared to BPA in reducing LDL-C \[time-adjusted percent change\] starting Day 30 and up to Day 150.

    Time frame: Baseline, from Day 30 up to Day 150

  6. Percent change from Baseline in LDL-C levels

    Assess efficacy of Inclisiran compared to BPA in reducing LDL-C \[time-adjusted percent change\] between Day 90 and Day 150.

    Time frame: Between Day 90 and Day 150

  7. Mean change from baseline in MMAS-8 over time

    Assess adherence to lipid-lowering therapy over time in participants receiving Inclisiran compared to BPA on top of maximally tolerated HI statins (+/- Ezetimibe) using the Morisky 8-Item Medication Adherence Scale (MMAS-8). The Morisky Medication Adherence Scale is an assessment tool used to measure non-adherence in patient populations. It consists of seven yes/no questions and one 5-point Likert scale with a sum score ranging between 0 and 8 points. The higher score indicates higher adherence.

    Time frame: From Baseline up to Day 150

  8. Mean change from Baseline in TSQM over time

    Assess effect of Inclisiran compared to BPA regarding treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM v. II). The TSQM (version II) comprises 11 items across four domains focusing on effectiveness (two items), side effects (four items), convenience (three items), and global satisfaction (two item) of the medication over the previous weeks, or since the patient's last use. With the exception of item 3 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). The 7-item scales had a nonneutral midpoint, such that there were more positive response options than negative response options, to allow for precise information to be obtained at the upper end of the score distribution. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100. Higher scores indicating higher patient satisfaction with medication.

    Time frame: From Baseline up to Day 150

  9. Mean change from Baseline in SF-BPI over time

    Assess the effect of Inclisiran compared to BPA regarding pain-related quality of life using the Short Form Brief Pain Inventory (SF-BPI). The SF-BPI is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The SF-BPI includes two main scores: a pain severity score and a pain interference score. The pain severity score combines the information of the four items about pain intensity, which are rated from 0, no pain, to 10, pain as bad as you can imagine. To derive the pain severity score the average of the four items will be taken. The pain interference is calculated similarly using the seven items regarding pain interference, which are rated from 0, does not interfere, to 10, completely interferes. The pain interference score will be the average of these seven items. Both scores will be between 0 and 10. Higher scores correspond to a poorer condition of the participant.

    Time frame: From Baseline up to Day 150

  10. Proportion of participants with clinically significant change from Baseline in SF-BPI

    Proportion of participants with clinically significant change from Baseline \[Minimal clinically important difference of 2 points\] in SF-BPI, to assess the effect of Inclisiran compared to BPA regarding pain-related quality of life using the Short Form Brief Pain Inventory (SF-BPI).

    Time frame: At day 150

07

Study locations

55 sites
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68305, Germany
  • Novartis Investigative Site
    Stuttgart, Baden-Wurttemberg 70376, Germany
  • Novartis Investigative Site
    Lichtenfels, Bavaria 96215, Germany
  • Novartis Investigative Site
    Muehldorf Am Inn, Bavaria 84453, Germany
  • Novartis Investigative Site
    Regensburg, Bavaria 93053, Germany
  • Novartis Investigative Site
    Sulzbach-Rosenberg, Bavaria 92237, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60389, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60594, Germany
  • Novartis Investigative Site
    Offenbach, Hesse 63065, Germany
  • Novartis Investigative Site
    Göttingen, Lower Saxony 37075, Germany
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50733, Germany
  • Novartis Investigative Site
    Essen, North Rhine-Westphalia 45355, Germany
  • Novartis Investigative Site
    Löhne, North Rhine-Westphalia 32584, Germany
  • Novartis Investigative Site
    Kaiserslautern, Rhineland-Palatinate 67655, Germany
  • Novartis Investigative Site
    Saint Ingbert, Saarland 66386, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01099, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04209, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Bad Homburg, 61348, Germany
  • Novartis Investigative Site
    Bad Krozingen, 79189, Germany
  • Novartis Investigative Site
    Bad Oeynhausen, 32545, Germany
  • Novartis Investigative Site
    Bamberg, 96049, Germany
  • Novartis Investigative Site
    Berlin, 10367, Germany
  • Novartis Investigative Site
    Berlin, 13347, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bochum, 44789, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bremen, 28277, Germany
  • Novartis Investigative Site
    Dessau, 06846, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Erfurt, 99097, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Essen, 45355, Germany
  • Novartis Investigative Site
    Falkensee, 14612, Germany
  • Novartis Investigative Site
    Gladbeck, 45968, Germany
  • Novartis Investigative Site
    Hamburg, 21109, Germany
  • Novartis Investigative Site
    Hamburg, 22041, Germany
  • Novartis Investigative Site
    Hamburg, 22607, Germany
  • Novartis Investigative Site
    Hoyerswerda, 02977, Germany
  • Novartis Investigative Site
    Kassel, 34121, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Ludwigshafen, 67067, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Markkleeberg, 04416, Germany
  • Novartis Investigative Site
    Meissen, 01662, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Papenburg, 26871, Germany
  • Novartis Investigative Site
    Pirna, 01796, Germany
  • Novartis Investigative Site
    Potsdam, 14471, Germany
  • Novartis Investigative Site
    Rüdersdorf, 15562, Germany
  • Novartis Investigative Site
    Ulm, 89077, Germany
  • Novartis Investigative Site
    Völklingen, 66333, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Dec 2025, 17 months.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 29, 2024
StartActual
Jun 21, 2024
Primary completionActual
Dec 1, 2025
CompletionActual
Jan 2, 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06431763
Responsible party
Sponsor
First posted
May 29, 2024
Start date
Jun 21, 2024
Primary completion
Dec 1, 2025
Completion
Jan 2, 2026
Last update
Jul 29, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion